Beneficial Ownership Report · SCHEDULE 13G
Nurix Therapeutics, Inc.
NRIXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Nurix Therapeutics, Inc.
- Company CIK
- 0001549595
- Street
- 1600 SIERRA POINT PKWY
- City
- BRISBANE
- State / country code
- CA
- Postal code
- 94005
Statement details
- Security class
- Common Stock, par value $0.001 per share
- Event date
- 09/16/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Perceptive Advisors LLC
- Citizenship / organization
- DE
- Reporting person type
- IA
- Group designation
- b
- Aggregate amount owned
- 5,536,629
- Percent of class
- 5.3
- Sole voting power
- 0
- Shared voting power
- 5,536,629
- Sole dispositive power
- 0
- Shared dispositive power
- 5,536,629
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Joseph Edelman
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- b
- Aggregate amount owned
- 5,536,629
- Percent of class
- 5.3
- Sole voting power
- 0
- Shared voting power
- 5,536,629
- Sole dispositive power
- 0
- Shared dispositive power
- 5,536,629
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Perceptive Life Sciences Master Fund, Ltd.
- Citizenship / organization
- E9
- Reporting person type
- CO
- Group designation
- b
- Aggregate amount owned
- 5,536,629
- Percent of class
- 5.3
- Sole voting power
- 0
- Shared voting power
- 5,536,629
- Sole dispositive power
- 0
- Shared dispositive power
- 5,536,629
- Aggregate excludes certain shares
- N
Item 1
Issuer
Nurix Therapeutics, Inc.
Principal executive office address
1600 Sierra Point Parkway, Brisbane, CA 94005
Item 2
Citizenship
Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
Filing person
The names of the persons filing this report (collectively, the "Reporting Persons") with respect to the Common Stock, par value $0.001 per share (the "Common Stock") of Nurix Therapeutics, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
Principal business or residence address
The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
Item 3
Not applicable indication
Y
Item 4
Percent of class
Perceptive Advisors: 5.3% Mr. Edelman: 5.3% Master Fund: 5.3%
Amount beneficially owned
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages are based on 103,781,683 shares of Common Stock outstanding as of June 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 9, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 5,536,629 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own shares held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the shares held by the Master Fund.
Sole voting power
Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
Shared voting power
Perceptive Advisors: 5,536,629 Mr. Edelman: 5,536,629 Master Fund: 5,536,629
Sole dispositive power
Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
Shared dispositive power
Perceptive Advisors: 5,536,629 Mr. Edelman: 5,536,629 Master Fund: 5,536,629
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 99.1 - Joint Filing Agreement
Signature 1
- Reporting person
- Perceptive Advisors LLC
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman, Managing Member
- Date
- 09/23/2026
Signature 2
- Reporting person
- Joseph Edelman
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman
- Date
- 09/23/2026
Signature 3
- Reporting person
- Perceptive Life Sciences Master Fund, Ltd.
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman, Managing Member
- Date
- 09/23/2026
Company context
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, SAR448272/NX-3911, in collaboration with Sanofi, a clinical stage degrader of IRAK4, GS6791, in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by Vestal Point Capital, LP regarding Nurix Therapeutics, Inc.Aug 14, 2026
- SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Nurix Therapeutics, Inc.Aug 14, 2026
- SCHEDULE 13G filingJul 31, 2026
- 10-Q filingJul 9, 2026
- Results of Operations and Financial ConditionJul 9, 2026